How should Chinese pharmaceutical enterprises participate in the world market?

Source: 2014-09-05 guide of China Galaxy Securities Network: Recently, the State Food and Drug Administration accepted the clinical project of "Herceptin" generic drugs by Sinopharm, which means the domestic competition of the generic drugs is upgrading Before that, Fosun medicine, CITIC Guojian, etc were all ahead of others in the application of the medicine, and a "post Herceptin" war was about to start The battle for "Herceptin" is only a microcosm of the era of post patent biopharmaceuticals According to the latest data of AMR, an international pharmaceutical industry research organization, 10 influential biopharmaceuticals will lose patent protection in the next four years, with a total sales volume of 60 billion US dollars Multinational pharmaceutical companies are facing more and more operating pressure due to the gradual expiration of heavy drug patent rights, the rising cost of innovative drug research and development, and the low price of medical reform Multinational pharmaceutical giants such as Johnson & Johnson, Bayer, Roche and Pfizer have to adjust their original vertical integration mode to return their business to the core On the one hand, before the expiration of the patent, we should actively authorize generic drugs to the cooperative companies to resist the competition of generic drugs and continue to share the market harvest; at the same time, we should gradually decompose the research, development, production, sales and other business links of innovative drugs and outsource some projects The Asian market has relatively cheap factor prices and huge market space, and relevant institutions in India, China and other markets often become their preferred partners Indian pharmaceutical companies are undoubtedly the big stars in the emerging generic pharmaceutical market Before 2000, they were mainly engaged in the production of low-cost APIs and pharmaceutical products, and the export countries were mainly in Russia, Africa and other non-standard markets In 2005, the large local pharmaceutical enterprises completed the transformation and transformation quickly Now it seems that many practices of Indian pharmaceutical companies at that time were far sighted, such as increasing investment in research and development, laying out bio medicine with heavy money, and gradually accumulating advantages in the development of original research drugs For another example, it actively seeks opportunities for cross-border M & A, and constantly integrates resources, thereby successfully entering mature standard markets such as the United States, Germany and the United Kingdom Last year, India's drug exports totaled between $13 billion and $14 billion, making it the second largest source of us generic imports "China's pharmaceutical enterprises are also facing a rare strategic opportunity to actively cooperate with multinational giants and learn relevant technology, business and capital operation experience, which is conducive to improving the future development space." Wang Zhuowei of Shennong private equity medicine has been observing the pharmaceutical industry all the year round In his opinion, constantly adjusting the internationalization path is the key to the success of Indian pharmaceutical enterprises, which is worth learning from in China How should Chinese pharmaceutical enterprises participate in the world market? Luo Jiarong, an industry analyst at Shenyin Wanguo, summed up several "moves" Starting from the product side, enterprises in the future can choose to join the global production chain of multinational enterprises or obtain overseas market standard certification to form high value-added exports in the form of preparations, etc.; the development of the business side can be completed through merger and acquisition of overseas enterprises or by merger and acquisition; in the field of technology, project cooperation can accelerate the acquisition of the latest R & D technology, of course, the enterprises that master patent technology can also In terms of capital, overseas listing of enterprises can easily obtain the required capital services